SLGL Key Statistics, Chart & Performance
The current stock price of SLGL is 42.14 USD. In the past month the price increased by 8.81%. In the past year, price increased by 286.61%.
SLGL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.87 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.94 | 498.60B | ||
| MRK | MERCK & CO. INC. | 11.95 | 261.26B | ||
| PFE | PFIZER INC | 7.78 | 141.57B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.22 | 109.81B | ||
| ZTS | ZOETIS INC | 19.85 | 55.45B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 22.30B | ||
| VTRS | VIATRIS INC | 5.34 | 14.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.57 | 11.24B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.21B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.58B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.42B |
Related stock screener links
About SLGL
Company Profile
Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
Company Info
SOL-GEL TECHNOLOGIES LTD
Golda Meir 7
Ness Ziona 7403648 IL
CEO: Alon Seri-Levy
Employees: 34
Phone: 97289313433
SOL-GEL TECHNOLOGIES LTD / SLGL FAQ
Can you describe the business of SOL-GEL TECHNOLOGIES LTD?
Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
What is the current price of SLGL stock?
The current stock price of SLGL is 42.14 USD. The price decreased by -0.75% in the last trading session.
What is the dividend status of SOL-GEL TECHNOLOGIES LTD?
SLGL does not pay a dividend.
What is the ChartMill technical and fundamental rating of SLGL stock?
SLGL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the sector and industry classification for SOL-GEL TECHNOLOGIES LTD?
SOL-GEL TECHNOLOGIES LTD (SLGL) operates in the Health Care sector and the Pharmaceuticals industry.
Is SOL-GEL TECHNOLOGIES LTD (SLGL) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SLGL.
What is the ownership structure of SOL-GEL TECHNOLOGIES LTD (SLGL)?
You can find the ownership structure of SOL-GEL TECHNOLOGIES LTD (SLGL) on the Ownership tab.
SLGL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SLGL. When comparing the yearly performance of all stocks, SLGL is one of the better performing stocks in the market, outperforming 98.99% of all stocks.
SLGL Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SLGL. No worries on liquidiy or solvency for SLGL as it has an excellent financial health rating, but there are worries on the profitability.
SLGL Financial Highlights
Over the last trailing twelve months SLGL reported a non-GAAP Earnings per Share(EPS) of -10.1. The EPS decreased by -54.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.68% | ||
| ROE | -10.7% | ||
| Debt/Equity | 0 |
SLGL Forecast & Estimates
7 analysts have analysed SLGL and the average price target is 51 USD. This implies a price increase of 21.03% is expected in the next year compared to the current price of 42.14.
For the next year, analysts expect an EPS growth of 97.17% and a revenue growth 870.39% for SLGL